EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 29 / No 6-7 (Juin–Juillet 2013) Med Sci (Paris), 29 6-7 (2013) 607-616 References
Free Access
Issue
Med Sci (Paris)
Volume 29, Number 6-7, Juin–Juillet 2013
Page(s) 607 - 616
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013296013
Published online 12 July 2013
  1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009 ; 34 : 1219–1263. [CrossRef] [PubMed] [Google Scholar]
  2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004 ; 351 : 1425–1436. [CrossRef] [PubMed] [Google Scholar]
  3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 ; 54 : S43–S54. [CrossRef] [PubMed] [Google Scholar]
  4. Girerd B, Montani D, Eyries M, et al. Absence of influence of gender, BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010 ; 11 : 73. [CrossRef] [PubMed] [Google Scholar]
  5. O’Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011 ; 8 : 526–538. [CrossRef] [PubMed] [Google Scholar]
  6. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010 ; 122 : 156–163. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  7. Perros F, Montani D, Dorfmuller P, et al. Nouvelles approches immunopathologiques de l’HTAP. Presse Med 2011 ; 40 Suppl 1 : 1S3–13. [CrossRef] [PubMed] [Google Scholar]
  8. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005 ; 60 : 765–772. [CrossRef] [PubMed] [Google Scholar]
  9. Terrier B, Tamby MC, Camoin L, et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 2010 ; 69 : 428–433. [CrossRef] [PubMed] [Google Scholar]
  10. Terrier B, Tamby MC, Camoin L, et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008 ; 177 : 1128–1134. [CrossRef] [PubMed] [Google Scholar]
  11. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008 ; 58 : 521–531. [CrossRef] [PubMed] [Google Scholar]
  12. Pugh ME, Hemnes AR. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl) 2010 ; 6 : 285–296. [CrossRef] [PubMed] [Google Scholar]
  13. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, et al. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun 2012 ; 38 : J109–J119. [CrossRef] [PubMed] [Google Scholar]
  14. Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 186 : 892–896. [CrossRef] [PubMed] [Google Scholar]
  15. Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010 ; 56 : 696–708. [CrossRef] [PubMed] [Google Scholar]
  16. Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005 ; 26 : 1110–1118. [CrossRef] [PubMed] [Google Scholar]
  17. Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 185 : 311–321. [CrossRef] [PubMed] [Google Scholar]
  18. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a french nationwide prospective multicenter study. Arthritis Rheum 2005 ; 52 : 3792–3800. [CrossRef] [PubMed] [Google Scholar]
  19. Fois E, Le Guern V, Dupuy A, et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 2010 ; 28 : 836–841. [PubMed] [Google Scholar]
  20. Chu JW, Kao PN, Faul JL, et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002 ; 122 : 1668–1673. [CrossRef] [PubMed] [Google Scholar]
  21. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008 ; 177 : 108–113. [CrossRef] [PubMed] [Google Scholar]
  22. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009 ; 119 : 1518–1523. [CrossRef] [PubMed] [Google Scholar]
  23. Austin ED, Rock MT, Mosse CA, et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med 2010 ; 104 : 454–462. [CrossRef] [PubMed] [Google Scholar]
  24. Ulrich S, Nicolls MR, Taraseviciene L, et al. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 2008 ; 75 : 272–280. [CrossRef] [PubMed] [Google Scholar]
  25. Huertas A, Tu L, Gambaryan N, et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J 2012 ; 40 : 895–904. [CrossRef] [PubMed] [Google Scholar]
  26. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 186 : 897–908. [CrossRef] [PubMed] [Google Scholar]
  27. Tamosiuniene R, Tian W, Dhillon G, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 2011 ; 109 : 867–879. [CrossRef] [PubMed] [Google Scholar]
  28. Perros F, Cohen-Kaminsky S, Humbert M. Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension. Respiration 2008 ; 75 : 253–256. [CrossRef] [PubMed] [Google Scholar]
  29. Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996 ; 23 : 286–290. [PubMed] [Google Scholar]
  30. Riboldi P, Gerosa M, Raschi E, et al. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003 ; 207 : 29–36. [CrossRef] [PubMed] [Google Scholar]
  31. Bussone G, Tamby MC, Calzas C, et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis 2012 ; 71 : 596–605. [CrossRef] [PubMed] [Google Scholar]
  32. Renaudineau Y, Dugue C, Dueymes M, et al. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002 ; 1 : 365–372. [CrossRef] [PubMed] [Google Scholar]
  33. Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998 ; 25 : 462–466. [PubMed] [Google Scholar]
  34. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995 ; 151 : 1628–1631. [CrossRef] [PubMed] [Google Scholar]
  35. Farha S, Sharp J, Asosingh K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ 2012 ; 2 : 220–228. [CrossRef] [PubMed] [Google Scholar]
  36. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature 2002 ; 420 : 875–878. [CrossRef] [PubMed] [Google Scholar]
  37. Arends SJ, Damoiseaux J, Duijvestijn A, et al. Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension. Eur Respir J 2010 ; 35 : 923–925. [CrossRef] [PubMed] [Google Scholar]
  38. Rose NR. Bona C Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today 1993 ; 14 : 426–430. [CrossRef] [PubMed] [Google Scholar]
  39. Yeager M, Cripe PJ, Colvin KL, et al. Loss of tolerance associated with bronchus associated lymphoid tissue expansion in pulmonary hypertension. Am J Respir Crit Care Med 2012 ; 185 : A4761. [Google Scholar]
  40. Quismorio FP, Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984 ; 13 : 349–359. [CrossRef] [PubMed] [Google Scholar]
  41. Carragher DM, Rangel-Moreno J, Randall TD. Ectopic lymphoid tissues and local immunity. Semin Immun 2008 ; 20 : 26–42. [CrossRef] [Google Scholar]
  42. Price LC, Montani D, Tcherakian C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011 ; 37 : 813–822. [CrossRef] [PubMed] [Google Scholar]
  43. Ogawa A, Nakamura K, Mizoguchi H, et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011 ; 183 : 139–140. [CrossRef] [PubMed] [Google Scholar]
  44. Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 2008 ; 17 : 754–756. [CrossRef] [PubMed] [Google Scholar]
  45. Semerano L, Boissier MC. Les anticorps monoclonaux dans les maladies immunes inflammatoires chroniques. Med Sci (Paris) 2009 ; 25 : 1108–1112. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  46. Tanaka Y. Diagnosis and therapy for systemic lupus erythematosus. Nihon Naika Gakkai Zasshi 2007 ; 96 : 2159–2164. [CrossRef] [PubMed] [Google Scholar]
  47. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005 ; 52 : 501–513. [CrossRef] [PubMed] [Google Scholar]
  48. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012 ; 33 : 571–577. [CrossRef] [PubMed] [Google Scholar]
  49. Kishimoto T. Interleukin-6 and its receptor in autoimmunity. J Autoimmun 1992 ; 5 Suppl A : 123–132. [CrossRef] [PubMed] [Google Scholar]
  50. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circulation Res 2009 ; 104 : 236–244. [Google Scholar]
  51. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010 ; 122 : 920–927. [CrossRef] [PubMed] [Google Scholar]
  52. Karavolias GK, Georgiadou P, Gkouziouta A, et al. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Expert Opin Ther Targets 2010 ; 14 : 1283–1289. [CrossRef] [PubMed] [Google Scholar]
  53. Furuya Y, Satoh T, Kuwana M., Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol 2010 ; 2010 : 720305. [PubMed] [Google Scholar]
  54. Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease. Heart Vessels 2010 ; 25 : 444–447. [CrossRef] [PubMed] [Google Scholar]
  55. Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman’s disease. Int J Hematol 2009 ; 90 : 99–102. [CrossRef] [PubMed] [Google Scholar]
  56. Terrier B, Mouthon L. Lupus érythémateux systémique. Med Sci (Paris) 2013 ; 29 : 65–73. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  57. Cartron G, Rossi JF. Anticorps monoclonaux thérapeutiques en oncohématologie. Med Sci (Paris) 2009 ; 25 : 1085–1089. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.